These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Van Damme L; Wright A; Depraetere K; Rosenstein I; Vandersmissen V; Poulter L; McKinlay M; Van Dyck E; Weber J; Profy A; Laga M; Kitchen V Sex Transm Infect; 2000 Apr; 76(2):126-30. PubMed ID: 10858715 [TBL] [Abstract][Full Text] [Related]
5. Guiding the vaginal microbicide trials with biomarkers of inflammation. Fichorova RN J Acquir Immune Defic Syndr; 2004 Oct; 37 Suppl 3(Suppl 3):S184-93. PubMed ID: 16419271 [TBL] [Abstract][Full Text] [Related]
6. Toward early safety alert endpoints: exploring biomarkers suggestive of microbicide failure. Mauck CK; Lai JJ; Weiner DH; Chandra N; Fichorova RN; Dezzutti CS; Hillier SL; Archer DF; Creinin MD; Schwartz JL; Callahan MM; Doncel GF AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1475-86. PubMed ID: 23885658 [TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. Mayer KH; Karim SA; Kelly C; Maslankowski L; Rees H; Profy AT; Day J; Welch J; Rosenberg Z; AIDS; 2003 Feb; 17(3):321-9. PubMed ID: 12556685 [TBL] [Abstract][Full Text] [Related]
8. Colposcopy: still useful in microbicide safety trials? Mauck CK; Weiner DH; Lai JJ; Schwartz JL Sex Transm Dis; 2012 Jun; 39(6):465-9. PubMed ID: 22592833 [TBL] [Abstract][Full Text] [Related]
9. Phase I safety & preliminary acceptability of nonoxynol-9 vaginal pessary as a vaginal microbicide in low risk women in Pune, India. Joshi S; Joglekar N; Ghate M; Unni J; Risbud A; Bentley M; Shepherd M; Bollinger R; Mehendale S Indian J Med Res; 2003 Apr; 117():152-7. PubMed ID: 14604303 [TBL] [Abstract][Full Text] [Related]
10. Introduction: background, issues, and recommendations from the conference. Mauck C J Acquir Immune Defic Syndr; 2004 Oct; 37 Suppl 3():S143-9. PubMed ID: 16419262 [No Abstract] [Full Text] [Related]
11. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. Van Damme L; Niruthisard S; Atisook R; Boer K; Dally L; Laga M; Lange JM; Karam M; Perriens JH AIDS; 1998 Mar; 12(4):433-7. PubMed ID: 9520174 [TBL] [Abstract][Full Text] [Related]
12. A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II. Mauck CK; Weiner DH; Creinin MD; Barnhart KT; Callahan MM; Bax R Contraception; 2004 Sep; 70(3):233-40. PubMed ID: 15325893 [TBL] [Abstract][Full Text] [Related]